Join partners Takeshi Nakao (Tokyo) and Vinita Kailasanath (Silicon Valley) for the latest episode of the Freshfields MedTech podcast. With a focus on Japan and the US, they discuss trends and innovations in MedTech, and potential risk and regulation that companies with MedTech products and services face.
Introduction (English translation): Hello everyone. My name is Takeshi, Managing Partner of Freshfields Tokyo Office. In today's podcast, we will discuss MedTech. MedTech is the word combining “medical” and “technology”, referring to using IOT and other technologies in healthcare. I will ask the speaker about this area, starting with the definition, which I am sure many of you have heard recently. Technology developments have led to many innovations in the field of healthcare, making it one of the growth areas and an area of high interest. Today I would like to bring you together with an expert in this field from the United States, Vinita Kailasanath. Vinita is the head of Freshfields' MedTech practice and has extensive experience in the field, particularly where both life sciences and technology are concerned. She has been involved in transactions that are strategically very important to our clients in the MedTech and digital health sectors. She provides advice in licensing transactions, research and development, and those kinds of areas. In fact, before becoming a lawyer, Vinita was doing research in the field of neuroendocrinology at the graduate level, which is a word I looked up in the dictionary. She also has experience providing marketing and sales support to pharmaceutical and biotech companies.
Outro (English translation): This time, we started with a high-level conversation with the theme of MedTech, explaining recent trends in regulations. Vinita is an expert in the field of MedTech, and we would like to send you another podcast when we hear about new developments as new trends emerge, etc.. Thank you for listening.
MedTech - A Conversation with Gloria Seibert
Tax Matters podcast: How will the UK Autumn Statement 2022 affect your business?
Essential Antitrust #23: Merger challenges in US courts: deciphering US antitrust agencies’ recent string of defeats
Great (stakeholder) expectations: Episode 4 - Activists all around
Great (stakeholder) expectations: Episode 3 - A bastion of support for social issues
Great (stakeholder) expectations: Episode 2 - Unpacking the status of climate disclosures
State of play on Pillar Two
Great (stakeholder) expectations: Episode 1 - A turning point for ESG
Essential Antitrust Asia #7: Key antitrust issues in Japan
Managing Risk in Asia #6: Managing transactional risks in life science investments in Asia
Tax matters: what is the impact of the proposed restrictions to the UK sovereign immunity tax exemption?
A new European AML authority – A year on
MedTech and Health Equity for Women - A Conversation with Marissa Fayer
Essential Antitrust #22: Global focus on labor: not necessarily business as usual
Does the proposed UK corporate re-domiciliation regime measure up?
Essential Antitrust #21: New EU and UK distribution rules for the next decade: check for compliance and new opportunities
Essential Foreign Investment #4: Expanding areas of global regulation
Essential Antitrust Asia #6: Key updates and enforcement trends in Hong Kong
Fintech in focus: Buy now, pay later
Navigating risks: tax disputes and privilege
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
Aligned Money Show
Gorse Culture PODcast : The H.R. Detective Agency!
HCI Leadership Revolution
The Ramsey Show
Planet Money